🟢 Alzamend Neuro is trading 6.4% up today after its annual report detailed trial timelines and funding requirements

Alzamend Neuro is trading at $1.34 (6.4% up) after investors digested its latest annual report detailing an $8.8 million loss and funding shortfall for clinical trials.

• The filing outlined timelines for AL001 Phase II bipolar disorder topline data, which is now expected in Q4 2026.
• Delays in the ALZN002 cell-based vaccine trial have kept market attention focused on the company’s cash runway and upcoming development milestones.